CSE:ACOG - Post Discussion
Post by
XeniaTechie on Nov 25, 2021 2:24pm
Alpha Cognition CEO talks update on clinical programs
Don't miss this update with $ACOG CEO, providing an update on clinical programs. Consider these catalysts moving into '22 - top line data read out expected in Q1/2 '22, patient tolerability trials commence early '22, interim readout in latter '22, & plans to file NDA for its lead compound representing near product approval. https://www.youtube.com/watch?v=VHCjmN1dR9g&ab_channel=SNNNetwork
Be the first to comment on this post